Advanced Filters
noise

Waltham, Massachusetts Clinical Trials

A listing of Waltham, Massachusetts clinical trials actively recruiting patient volunteers.

Found 1,797 clinical trials
M Michael Jaklitsch, MD

Geriatric Thoracic Surgery Ambulation Challenge

This study is examining collecting data on steps walked (ambulation) per day by thoracic surgery patients over the age of 65 years-old before surgery. The name(s) of the study device involved in this study is: Fitbit inspire

65 years of age All Phase N/A
N Nadine Tung, MD

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) Hormonal …

18 years of age All Phase 2

The HALT Biomarker Study

The purpose of the HALT Biomarkers study are to identify a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT) and can be used to supplement the diagnosis of HALT; to characterize changes in circulating proteins after treatment of HALT with systemic anticoagulation; and …

65 years of age All Phase 1

Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies

The goal of this clinical trial is to assess the effect of PRP/PPP/BMAC application on functional outcomes after hip arthroscopy to address acetabular labral pathologies. The main questions it aims to answer are: Does PRP/PPP/BMAC application improve functional outcomes after hip arthroscopy to address acetabular labral pathologies? Does PRP/PPP/BMAC application …

18 years of age All Phase 3
S Sue Quinsey

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 in patients with recurrent advanced/metastatic cancer, including hormone …

18 years of age All Phase 1/2
N Natalie Sinclair

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (Trodelvy™;IMMU-132) Pembrolizumab (Keytruda®; MK-3475)

18 years of age All Phase 2
M Michael Parsons, PhD

Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer

This research study evaluates the effect of chemotherapy on cognition (thinking) and the brain in people with breast cancer.

60 years of age Female Phase N/A
E Eva Wu

Gamma-Music Based Intervention for Mild Alzheimer's Disease

The study will test and refine a novel brain-stimulation tool using gamma-frequency lights coupled with self-selected music for a gamma-music-based intervention for participants with mild Alzheimer's Disease. Results will yield a gamma-stimulation protocol that reliably influences brain activity (Aim 1), is adaptive, motivating and rewarding to use (Aim 2), and …

50 - 95 years of age All Phase N/A
M Mina Sedrak

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.

70 years of age All Phase 2
C Carrie Smith

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of APG-2575.

18 - 85 years of age All Phase 1

Simplify language using AI